Ovarian Cancer

In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline. Read Article ›

Results from the phase 3 ARIEL3 clinical trial showed that maintenance therapy with rucaparib leads to significantly improved progression-free survival in patients with advanced ovarian cancer and non-BRCA homologous recombinant repair gene mutations. Read Article ›

At the 12-month landmark analysis of the single-arm phase 2 OVARIO clinical trial, 75% of patients in the overall population of patients with newly diagnosed stage IIIB-IV ovarian cancer remained progression-free. Read Article ›

Data from the phase 3 PAOLO-1 clinical trial showed that progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy. Read Article ›

The approval of 3 PARP inhibitors has made it feasible to personalize therapy for patients with ovarian cancer based on their mutation status as well as other factors, including the treatment setting. Read Article ›

The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients. Read Article ›

Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy. Read Article ›

According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years. Read Article ›

In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies. Read Article ›

The Centers for Medicare & Medicaid Services (CMS) has announced an expansion of coverage for telehealth services for Medicare beneficiaries. To qualify, 2-way real-time interactive communication between providers and patients using both audio and video technology is required. Read Article ›

Page 3 of 6

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: